Sandoz Group company profile
Company profile
Sandoz Group has 20,000 employees and is headquartered in Basel, Switzerland.
Sold worldwide, the generic and biosimilar medicines of Sandoz Group AG are developed, manufactured and marketed by the company across a wide range of therapeutic areas, including oncology, cardiovascular and central nervous system disorders, immunology, diabetes and ophthalmology. Its therapeutic coverage also extends to hematology, nephrology, neurology and endocrinology. Its offering includes active pharmaceutical ingredients and finished dosage forms. A strategic collaboration with Shanghai Henlius Biotech aims to broaden patient access to biosimilar medicines.
In the fiscal year ended December 2025, revenue reached 11.2 billion US dollars, up 7.4% from the prior year, and net income came to 914 million US dollars. The company employs 20,000 people and is headquartered in Basel, Switzerland, where it was founded in 1886.
Company facts
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- Switzerland
- Headquarters
- Centralbahnstrasse 4, 4051, Basel
- Employees
- 20,000
- Chief executive
- Richard Saynor
- Founded
- 1886
- Fiscal year
- January - December
- Listing
- SDZ · SIX
- Indices
- SMI
- Currency
- CHF
- ISIN
- CH1243598427
- Website
- sandoz.com
Sandoz Group and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| Sandoz GroupSDZ | Switzerland | $43.57B | 20,000 | 9.3% | 72.3 |
| HaleonHLN | United Kingdom | $40.15B | 24,535 | 23.5% | 19.3 |
| Galderma GroupGALD | Switzerland | $51.94B | 7,676 | 19.1% | 64.5 |
| MerckMRK | Germany | $71.52B | 61,949 | 17.0% | 33.9 |
| Swedish Orphan BiovitrumSOBI | Sweden | $16.27B | 2,207 | 30.9% | 25.0 |
| IpsenIPN | France | $14.2B | 5,535 | 27.4% | 25.5 |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
